Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Adverse events (Panaccione 2010) · induction of remission in Crohn's disease

Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.9 [0.75, 1.07]
1 study · 230 participants
Moderate

Serious adverse events (Panaccione 2010) · induction of remission in Crohn's disease

Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.52 [0.17, 1.61]
1 study · 246 participants
Low